Chemomab Therapeutics Ltd. (CMMB)
2.59
-0.10
(-3.72%)
USD |
NASDAQ |
Sep 10, 16:00
2.59
0.00 (0.00%)
After-Hours: 20:00
Chemomab Therapeutics Enterprise Value : 12.80M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 12.80M |
| September 08, 2026 | 13.24M |
| September 04, 2026 | 12.95M |
| September 03, 2026 | 13.82M |
| September 02, 2026 | 13.09M |
| September 01, 2026 | 13.09M |
| August 31, 2026 | 13.02M |
| August 28, 2026 | 12.95M |
| August 27, 2026 | 13.02M |
| August 26, 2026 | 12.08M |
| August 25, 2026 | 9.978M |
| August 24, 2026 | 9.036M |
| August 21, 2026 | 8.964M |
| August 20, 2026 | 8.311M |
| August 19, 2026 | 8.456M |
| August 18, 2026 | 7.152M |
| August 17, 2026 | 7.225M |
| August 14, 2026 | 7.152M |
| August 13, 2026 | 7.080M |
| August 12, 2026 | 7.225M |
| August 11, 2026 | 7.080M |
| August 10, 2026 | 7.007M |
| August 07, 2026 | 7.297M |
| August 06, 2026 | 6.355M |
| August 05, 2026 | 5.993M |
| Date | Value |
|---|---|
| August 04, 2026 | 5.486M |
| August 03, 2026 | 5.051M |
| July 31, 2026 | 4.544M |
| July 30, 2026 | 4.399M |
| July 29, 2026 | 3.892M |
| July 28, 2026 | 3.674M |
| July 27, 2026 | 3.602M |
| July 24, 2026 | 3.167M |
| July 23, 2026 | 3.457M |
| July 22, 2026 | 3.674M |
| July 21, 2026 | 3.964M |
| July 20, 2026 | 4.181M |
| July 17, 2026 | 4.616M |
| July 16, 2026 | 4.326M |
| July 15, 2026 | 4.326M |
| July 14, 2026 | 4.399M |
| July 13, 2026 | 5.268M |
| July 10, 2026 | 5.920M |
| July 09, 2026 | 6.572M |
| July 08, 2026 | 7.587M |
| July 07, 2026 | 13.38M |
| July 06, 2026 | 10.70M |
| July 02, 2026 | 9.760M |
| July 01, 2026 | 5.630M |
| June 30, 2026 | 5.051M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioLineRx Ltd. | 8.851M |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 415.34M |
| Can-Fite BioPharma Ltd. | -4.190M |
| Galmed Pharmaceuticals Ltd. | -6.624M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.202M |
| Total Expenses (Quarterly) | 2.202M |
| EPS Diluted (Quarterly) | -0.275 |
| Earnings Yield | -39.40% |
| Normalized Earnings Yield | -39.42 |